76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Ocugen Inc
Closed
0.69
Overview
Share price change
24h
Min
0.68
Max
0.72
Income | -1.5M -15M |
|---|---|
Sales | 717K 1.5M |
EPS | -0.05 |
Profit margin | -1,036.462 |
Employees | 95 |
EBITDA | -1.3M -15M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +804.29% upside |
Next Earnings | 7 Aug 2025 |
|---|
Market Cap | 28M 204M |
|---|---|
Previous open | 0.69 |
Previous close | 0.69 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Ocugen Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ocugen Inc Forecast
Price Target
By TipRanks
804.29% upside
12 Months Forecast
Average 6.33 USD 804.29%
High 8 USD
Low 4 USD
Based on 3 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
